We are live on
!
Find out more
SCA
Spearhead Capital Advisors Portfolio holdings
AUM
$92.3M
1-Year Est. Return
18.16%
This Fund
S&P 500
This Quarter
Est. Return
+7.56%
1 Year Est. Return
-18.16%
3 Year Est. Return
+25.24%
5 Year Est. Return
+54.04%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$57.8M
(+8.5%)
Cap. Flow
+$11.1M
Cap. Flow
% of AUM
1.5%
Top 10 Holdings %
Top 10 Hldgs %
31.1%
Holding
195
New
10
Increased
148
Reduced
29
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Golub Capital BDC
GBDC
|
+$2.33M |
| 2 |
Apple
AAPL
|
+$1.25M |
| 3 |
Bloom Energy
BE
|
+$903K |
| 4 |
ETRACS Alerian MLP Infrastructure Index ETN Series B due Apr 2 2040
MLPB
|
+$552K |
| 5 |
Salesforce
CRM
|
+$365K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kiniksa Pharmaceuticals
KNSA
|
+$2.15M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$601K |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$576K |
| 4 |
GLUU
Glu Mobile Inc.
GLUU
|
+$503K |
| 5 |
Moderna
MRNA
|
+$495K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.29% |
| 2 | Healthcare | 12.02% |
| 3 | Consumer Staples | 10.97% |
| 4 | Financials | 10.35% |
| 5 | Communication Services | 7.69% |
Similar funds
AAM
AEPBI
MW
SC
NIM
WIM
LAM
EFEM
Spearhead Capital Advisors's Q2 2021 Portfolio in Review
As of Q2 2021, Spearhead Capital Advisors held 195 positions worth $735M, up 8.5% from $677M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Spearhead Capital Advisors's Q2 2021 filing shows 10 new, 148 increased, 29 reduced and 4 closed positions. Its largest new stake was Golub Capital BDC: 150,000 shares worth $2.31M. The largest sale was Kiniksa Pharmaceuticals, an estimated $2.15M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Staples.
- Spearhead Capital Advisors's largest Q2 2021 buy was Golub Capital BDC: 150,000 shares worth $2.31M.
- Spearhead Capital Advisors added most to Apple in Q2 2021, an estimated $1.25M increase.
- Spearhead Capital Advisors's biggest Q2 2021 reduction was Kiniksa Pharmaceuticals, cutting an estimated $2.15M.
- Spearhead Capital Advisors fully exited GenMark Diagnostics, Inc in Q2 2021, selling an estimated $576K.
- Spearhead Capital Advisors's ten largest holdings make up 31% of its $735M portfolio in Q2 2021.
- Spearhead Capital Advisors opened 10 new positions and closed 4 in Q2 2021.
- Spearhead Capital Advisors's portfolio value rose 8.5% quarter-over-quarter to $735M.
Based on Spearhead Capital Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.